Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment

被引：29

作者：

Harzic, M ^{[1
]}

Pellegrin, I

Deveau, C

Chaix, ML

Dubeaux, B

Garrigue, I

Ngo, N

Rouzioux, C

Goujard, C

Hoen, B

Sereni, D

Delfraissy, JF

Meyer, L

机构：

[1] Ctr Hosp Versailles, Microbiol Serv, Le Chesnay, France

[2] Hop Pellegrin, Ser Virol, F-33076 Bordeaux, France

[3] Hop Bicetre, Serv Epidemiol, INSERM U292, Le Kremlin Bicetre, France

[4] Hop Bicetre, Serv Med Interne, AP HP, Le Kremlin Bicetre, France

[5] Hop Necker Enfants Malad, AP HP, Serv Virol, Paris, France

[6] Hop St Jacques, Serv Med Interne, F-25030 Besancon, France

[7] Hop St Louis, Serv Med Interne, AP HP, Paris, France

来源：

AIDS | 2002年 / 16卷 / 05期

关键词：

D O I：

10.1097/00002030-200203290-00017

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A key resistance mutation on the reverse transcriptase gene was observed in 8.8% of 204 patients enrolled during primary infection between 1996 and 1999 in ANRS 053 and the PRIMO cohort; the prevalence was stable over time. The prevalence of key protease gene mutations increased from 0% in 1996 to 8.3% in 1999. After the initiation of highly active antiretroviral therapy, HIV RNA in patients with one or more resistance to a prescribed drug decreased to under 20-50 copies/ml more slowly than in other patients.

引用

页码：793 / 796

页数：4

共 15 条

[1] Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users [J].

Alexander, CS ;

Dong, W ;

Schechter, MT ;

O'Shaughnessy, MV ;

Strathdee, SA ;

Mo, T ;

Montaner, JSG ;

Harrigan, PR .

AIDS, 1999, 13 (08) :981-985

[2] HIV-1 drug resistance in newly infected individuals [J].

Boden, D ;

Hurley, A ;

Zhang, LQ ;

Cao, YZ ;

Guo, Y ;

Jones, E ;

Tsay, J ;

Ip, J ;

Farthing, C ;

Limoli, K ;

Parkin, N ;

Markowitz, M .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12) :1135-1141

[3] Weak anti-HIV CD8+ T-cell effector activity in HIV primary infection [J].

Dalod, M ;

Dupuis, M ;

Deschemin, JG ;

Goujard, C ;

Deveau, C ;

Meyer, L ;

Ngo, N ;

Rouzioux, C ;

Guillet, JG ;

Delfraissy, JF ;

Sinet, M ;

Venet, A .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (10) :1431-1439

[4]

Delfraissy JF, 2000, PRISE CHARGE THERAPE, P17

[5] BRIEF REPORT - PRIMARY INFECTION WITH ZIDOVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].

ERICE, A ;

MAYERS, DL ;

STRIKE, DG ;

SANNERUD, KJ ;

MCCUTCHAN, FE ;

HENRY, K ;

BALFOUR, HH .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (16) :1163-1165

[6]

HARZIC M, 1999, 3 INT WORKSH HIV DRU

[7] Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection:: Results of the ANRS 053 trial [J].

Hoen, B ;

Dumon, B ;

Harzic, M ;

Venet, A ;

Dubeaux, B ;

Lascoux, C ;

Bourezane, Y ;

Ragnaud, JM ;

Bicart-See, A ;

Raffi, F ;

Beauvais, L ;

Fleury, H ;

Séréni, D .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (04) :1342-1346

[8] Reduced antiretroviral drug susceptibility among patients with primary HIV infection [J].

Little, SJ ;

Daar, ES ;

D'Aquila, RT ;

Keiser, PH ;

Connick, E ;

Whitcomb, JM ;

Hellmann, NS ;

Petropoulos, CJ ;

Sutton, L ;

Pitt, JA ;

Rosenberg, ES ;

Koup, RA ;

Walker, BD ;

Richman, DD .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12) :1142-1149

[9] Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug [J].

Mammano, F ;

Trouplin, V ;

Zennou, V ;

Clavel, F .

JOURNAL OF VIROLOGY, 2000, 74 (18) :8524-8531

[10]

MAYERS DL, 1995, AIDS RES HUM RETROV, V11, pS162

← 1 2 →